What is quality of life? Clinical trials have long been dominated by clinically based endpoints, but research has proved that health-related quality of life (HRQoL) can only be captured accurately by patients themselves using patient-reported outcomes (PROs). The United States Food and Drug Administration defines PROs as the measurement of any aspect of a patient's health status that comes directly from the patient, that is, a measurement taken without interpretation of the patient's responses by a physician or anyone else. The EORTC QLQ-C30 is the most widely cancer specific HRQoL questionnaire used for PROs in the world. Developed in 1991 by the EORTC Quality of Life Group, it has been translated into more than 60 languages and has over 40 developed or under development cancer-specific modules. One of the key challenges faced is pooling data and performing meta-analyses of the results of closed trials. shown that health-related QoL (HRQoL) can only be captured accurately by the patients themselves using patient-reported outcomes (PROs).
Quality of Life
Clinical trials have long been dominated by clinically based endpoints such as overall survival (OS) and progression-free survival (PFS) to measure the effectiveness of a treatment. A 5-year OS rate, for example, indicates the percentage of patients alive after 5 years of treatment or 5 years after they were diagnosed. PFS indicates the length of time during which a patient's disease does not progress. Neither of these endpoints, however, measure a patient's quality of life (QoL), and research has shown that health-related QoL (HRQoL) can only be captured accurately by the patients themselves using patient-reported outcomes (PROs).
Patient-reported Outcomes
The United States Food and Drug Administration (FDA) defines PROs as the measurement of any aspect of patient's health status that comes directly from the patient, i.e. the patient's responses are not interpreted by a physician or anyone else. EORTC QLQ-C30 is the most widely cancer specific HRQoL questionnaire used in the world. Developed in 1991 by the EORTC Quality of Life Group, it is now translated and linguistically validated into more than 60 languages and can be extended with over 40 modules, addressing specific symptoms, treatments or cancer types. 
Better Efficacy Does Not Necessarily Mean Improved HRQoL
In EORTC trial 18991, 1,256 patients with stage III melanoma were randomly assigned to be observed, 629 patients, or to receive, 627 patients, pegylated interferon alpha-2b (PEG-IFN-α-2b) following lymphadenectomy. The results showed that adjuvant treatment with PEG-IFN-α-2b had, at 3.8 years median follow-up, a significant, sustained effect on recurrence-free survival (RFS) in these patients. 2 However, using the EORTC QLQ-C30, it was observed that the HRQoL of the patients in the PEG-IFN-α-2b arm was more impaired. 3 Patients in the PEG-IFN-α-2b arm reported lower scores on two functioning scales (social and role functioning) as well as on three symptom scales (appetite loss, fatigue and dyspnoea) than those in the observation arm. These results highlight the importance of considering HRQoL when making treatment decisions. 
HRQoL Plays Role in Practice-changing Trials

About the EORTC
The EORTC brings together European cancer clinical research experts from all disciplines for trans-national collaboration.
Both multinational and multidisciplinary, the EORTC Network comprises more than 2,000 collaborators from all disciplines involved in cancer treatment and research in more than 300 hospitals in over 30 countries.
Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug-evaluation programmes and medical practices.
EORTC Headquarters, a unique pan-European independent clinical research infrastructure, is based in Brussels, Belgium, from where its various activities are coordinated and run (visit www.eortc.org). n
